医学
艾司洛尔
变时性
心脏病学
随机对照试验
心肌梗塞
内科学
心房颤动
麻醉
心率
血压
作者
Shiavax J. Rao,Arjun Kanwal,Amreen Kanwal,Alexandrina Danilov,William H. Frishman
出处
期刊:Cardiology in Review
[Ovid Technologies (Wolters Kluwer)]
日期:2023-04-26
卷期号:Publish Ahead of Print
被引量:1
标识
DOI:10.1097/crd.0000000000000555
摘要
Landiolol is an ultra-short-acting, highly cardio-selective, β-blocker, that is currently approved for clinical use in Japan and the European Union, for the treatment of tachyarrhythmias. Landiolol is highly cardio-selective with high β1 selectivity and receptor affinity, resulting in a more potent chronotropic effect and less potent hypotensive effect compared with other β-blockers such as esmolol and propranolol. Based on the recent randomized controlled trials, low-dose landiolol may have a beneficial role in the prevention and management of postoperative atrial fibrillation following noncardiac and cardiac surgeries, including on-pump and off-pump coronary artery bypass grafting and valve surgery. Additionally, landiolol may have potential utility for myocardial salvage and prevention of postpercutaneous coronary intervention myocardial infarction. Furthermore, the use of landiolol may also have a therapeutic effect for rate control of sepsis-related tachyarrhythmias. Positive results of recent randomized controlled trials should continue to inspire clinicians to conduct further, larger studies, to find new potential clinical applications for this novel drug.
科研通智能强力驱动
Strongly Powered by AbleSci AI